Centre for Addiction and Mental Health, 250 College Street, Toronto, M5T 1R8, Canada.
Department of Psychiatry & Behavioral Sciences, University of California San Francisco, San Francisco, 94143, USA.
Alzheimers Res Ther. 2023 Jun 16;15(1):113. doi: 10.1186/s13195-023-01244-3.
Genome-wide association studies (GWAS) have indicated moderate genetic overlap between Alzheimer's disease (AD) and related dementias (ADRD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), neurodegenerative disorders traditionally considered etiologically distinct. However, the specific genetic variants and loci underlying this overlap remain almost entirely unknown.
We leveraged state-of-the-art GWAS for ADRD, PD, and ALS. For each pair of disorders, we examined each of the GWAS hits for one disorder and tested whether they were also significant for the other disorder, applying Bonferroni correction for the number of variants tested. This approach rigorously controls the family-wise error rate for both disorders, analogously to genome-wide significance.
Eleven loci with GWAS hits for one disorder were also associated with one or both of the other disorders: one with all three disorders (the MAPT/KANSL1 locus), five with ADRD and PD (near LCORL, CLU, SETD1A/KAT8, WWOX, and GRN), three with ADRD and ALS (near GPX3, HS3ST5/HDAC2/MARCKS, and TSPOAP1), and two with PD and ALS (near GAK/TMEM175 and NEK1). Two of these loci (LCORL and NEK1) were associated with an increased risk of one disorder but decreased risk of another. Colocalization analysis supported a shared causal variant between ADRD and PD at the CLU, WWOX, and LCORL loci, between ADRD and ALS at the TSPOAP1 locus, and between PD and ALS at the NEK1 and GAK/TMEM175 loci. To address the concern that ADRD is an imperfect proxy for AD and that the ADRD and PD GWAS have overlapping participants (nearly all of which are from the UK Biobank), we confirmed that all our ADRD associations had nearly identical odds ratios in an AD GWAS that excluded the UK Biobank, and all but one remained nominally significant (p < 0.05) for AD.
In one of the most comprehensive investigations to date of pleiotropy between neurodegenerative disorders, we identify eleven genetic risk loci shared among ADRD, PD, and ALS. These loci support lysosomal/autophagic dysfunction (GAK/TMEM175, GRN, KANSL1), neuroinflammation/immunity (TSPOAP1), oxidative stress (GPX3, KANSL1), and the DNA damage response (NEK1) as transdiagnostic processes underlying multiple neurodegenerative disorders.
全基因组关联研究 (GWAS) 表明,阿尔茨海默病 (AD) 和相关痴呆症 (ADRD)、帕金森病 (PD) 和肌萎缩侧索硬化症 (ALS) 之间存在中度遗传重叠,这些神经退行性疾病传统上被认为具有不同的病因。然而,这种重叠背后的具体遗传变异和基因座几乎完全未知。
我们利用了针对 ADRD、PD 和 ALS 的最先进的 GWAS。对于每一对疾病,我们检查了一种疾病的每一个 GWAS 命中,并测试它们是否也对另一种疾病具有显著性,对测试的变异数量应用了 Bonferroni 校正。这种方法严格控制了两种疾病的总体错误率,类似于全基因组显著性。
有 11 个与一种疾病的 GWAS 命中相关的基因座也与另一种或两种疾病相关:一个与所有三种疾病(MAPT/KANSL1 基因座)相关,五个与 ADRD 和 PD 相关(接近 LCORL、CLU、SETD1A/KAT8、WWOX 和 GRN),三个与 ADRD 和 ALS 相关(接近 GPX3、HS3ST5/HDAC2/MARCKS 和 TSPOAP1),两个与 PD 和 ALS 相关(接近 GAK/TMEM175 和 NEK1)。其中两个基因座(LCORL 和 NEK1)与一种疾病的风险增加和另一种疾病的风险降低有关。共定位分析支持 CLU、WWOX 和 LCORL 基因座之间 ADRD 和 PD 之间存在共同的因果变异,TSPOAP1 基因座之间 ADRD 和 ALS 之间存在共同的因果变异,以及 NEK1 和 GAK/TMEM175 基因座之间 PD 和 ALS 之间存在共同的因果变异。为了解决 ADRD 是 AD 的不完美替代物以及 ADRD 和 PD GWAS 有重叠参与者(几乎都来自 UK Biobank)的问题,我们在排除 UK Biobank 的 AD GWAS 中证实了我们所有的 ADRD 关联都具有几乎相同的比值比,并且除了一个之外,所有关联对于 AD 仍然具有名义显著性(p < 0.05)。
在迄今为止对神经退行性疾病之间的多效性进行的最全面的研究之一中,我们确定了 11 个与 ADRD、PD 和 ALS 共有的遗传风险基因座。这些基因座支持溶酶体/自噬功能障碍(GAK/TMEM175、GRN、KANSL1)、神经炎症/免疫(TSPOAP1)、氧化应激(GPX3、KANSL1)和 DNA 损伤反应(NEK1)作为多种神经退行性疾病的潜在共同发病机制。